Comparative Pharmacology
Head-to-head clinical analysis: CEFMAX versus CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFMAX versus CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER.
CEFMAX vs CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CEFMAX (cefepime) is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria and PBP-1a/1b in Gram-positive bacteria, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It has zwitterionic properties facilitating rapid penetration through Gram-negative outer membranes and is relatively resistant to hydrolysis by many beta-lactamases, including AmpC beta-lactamases.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. It is resistant to many beta-lactamases.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
1-2 g IV every 6-8 hours. Maximum 12 g/day.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 0.7-1.1 hours (normal renal function); prolonged to 5-13 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal (80–90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <5%.
Renal: 85-90% unchanged via glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic